EVANIUM builds ingredient formulations around its proprietary OPTISOLV® platform, a dual-coating system combining a cyclodextrin-based core with an outer phospholipid shell to stabilise actives in a crystal-free, highly dispersible state. The company says OPTISOLV prevents re-agglomeration, improves permeability, and raises solubility and absorption using natural materials; for curcumin it reports more than 1,000x improved solubility and over 170x greater release during digestion versus the native form. EVANIUM’s commercial portfolio includes OPTISOLV Curcumin, Berberine, Boswellia, and Passiflora, and it completed an initial commercial launch of OPTISOLV Curcumin in 2025 with Hevert-Arzneimittel. The company has filed its fourth patent to protect the platform and is preparing clinical studies to build scientific evidence for its formulations. Operationally, EVANIUM has grown to more than 12 employees and produced and delivered over two tons of material in 2026. Future plans emphasized in company statements include scaling manufacturing, expanding the team, advancing clinical work, and accelerating B2B commercial partnerships.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026